Rimonabant  ||| S:0 E:11 ||| NNP
for  ||| S:11 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
treatment  ||| S:19 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
overweight  ||| S:32 E:43 ||| NN
and  ||| S:43 E:47 ||| CC
obese  ||| S:47 E:53 ||| JJ
people  ||| S:53 E:60 ||| NNS
This  ||| S:60 E:65 ||| DT
paper  ||| S:65 E:71 ||| NN
presents  ||| S:71 E:80 ||| VBZ
a  ||| S:80 E:82 ||| DT
summary  ||| S:82 E:90 ||| NN
of  ||| S:90 E:93 ||| IN
the  ||| S:93 E:97 ||| DT
evidence  ||| S:97 E:106 ||| NN
review  ||| S:106 E:113 ||| NN
group  ||| S:113 E:119 ||| NN
( ||| S:119 E:120 ||| -LRB-
ERG ||| S:120 E:123 ||| NNP
)  ||| S:123 E:125 ||| -RRB-
report  ||| S:125 E:132 ||| NN
into  ||| S:132 E:137 ||| IN
the  ||| S:137 E:141 ||| DT
clinical  ||| S:141 E:150 ||| JJ
and  ||| S:150 E:154 ||| CC
cost-effectiveness  ||| S:154 E:173 ||| JJ
of  ||| S:173 E:176 ||| IN
rimonabant  ||| S:176 E:187 ||| NN
for  ||| S:187 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
treatment  ||| S:195 E:205 ||| NN
of  ||| S:205 E:208 ||| IN
obese  ||| S:208 E:214 ||| NN
or  ||| S:214 E:217 ||| CC
overweight  ||| S:217 E:228 ||| JJ
patients  ||| S:228 E:237 ||| NNS
based  ||| S:237 E:243 ||| VBN
upon  ||| S:243 E:248 ||| IN
a  ||| S:248 E:250 ||| DT
review  ||| S:250 E:257 ||| NN
of  ||| S:257 E:260 ||| IN
the  ||| S:260 E:264 ||| DT
manufacturer ||| S:264 E:276 ||| NN
's  ||| S:276 E:279 ||| POS
submission  ||| S:279 E:290 ||| NN
to  ||| S:290 E:293 ||| TO
the  ||| S:293 E:297 ||| DT
National  ||| S:297 E:306 ||| NNP
Centre  ||| S:306 E:313 ||| NNP
for  ||| S:313 E:317 ||| IN
Health  ||| S:317 E:324 ||| NNP
and  ||| S:324 E:328 ||| CC
Clinical  ||| S:328 E:337 ||| NNP
Excellence  ||| S:337 E:348 ||| NNP
( ||| S:348 E:349 ||| -LRB-
NICE ||| S:349 E:353 ||| NNP
)  ||| S:353 E:355 ||| -RRB-
as  ||| S:355 E:358 ||| IN
part  ||| S:358 E:363 ||| NN
of  ||| S:363 E:366 ||| IN
the  ||| S:366 E:370 ||| DT
single  ||| S:370 E:377 ||| JJ
technology  ||| S:377 E:388 ||| NN
appraisal  ||| S:388 E:398 ||| NN
( ||| S:398 E:399 ||| -LRB-
STA ||| S:399 E:402 ||| NNP
)  ||| S:402 E:404 ||| -RRB-
process ||| S:404 E:411 ||| NN
.  ||| S:411 E:413 ||| .
The  ||| S:413 E:417 ||| DT
submission ||| S:417 E:427 ||| NN
's  ||| S:427 E:430 ||| POS
main  ||| S:430 E:435 ||| JJ
evidence  ||| S:435 E:444 ||| NN
came  ||| S:444 E:449 ||| VBD
from  ||| S:449 E:454 ||| IN
four  ||| S:454 E:459 ||| CD
randomised  ||| S:459 E:470 ||| NNS
controlled  ||| S:470 E:481 ||| VBN
trials ||| S:481 E:487 ||| NNS
.  ||| S:487 E:489 ||| .
Rimonabant  ||| S:489 E:500 ||| NNP
resulted  ||| S:500 E:509 ||| VBD
in  ||| S:509 E:512 ||| IN
a  ||| S:512 E:514 ||| DT
significantly  ||| S:514 E:528 ||| RB
greater  ||| S:528 E:536 ||| JJR
benefit  ||| S:536 E:544 ||| NN
than  ||| S:544 E:549 ||| IN
placebo  ||| S:549 E:557 ||| NN
for  ||| S:557 E:561 ||| IN
all  ||| S:561 E:565 ||| DT
primary  ||| S:565 E:573 ||| JJ
weight  ||| S:573 E:580 ||| NN
loss  ||| S:580 E:585 ||| NN
outcomes ||| S:585 E:593 ||| NNS
.  ||| S:593 E:595 ||| .
At  ||| S:595 E:598 ||| IN
1  ||| S:598 E:600 ||| CD
year ||| S:600 E:604 ||| NN
,  ||| S:604 E:606 ||| ,
rimonabant  ||| S:606 E:617 ||| NN
had  ||| S:617 E:621 ||| VBD
a  ||| S:621 E:623 ||| DT
statistically  ||| S:623 E:637 ||| JJ
significant  ||| S:637 E:649 ||| JJ
beneficial  ||| S:649 E:660 ||| JJ
effect  ||| S:660 E:667 ||| NN
on  ||| S:667 E:670 ||| IN
systolic  ||| S:670 E:679 ||| JJ
blood  ||| S:679 E:685 ||| NN
pressure ||| S:685 E:693 ||| NN
,  ||| S:693 E:695 ||| ,
high-density  ||| S:695 E:708 ||| JJ
lipoprotein  ||| S:708 E:720 ||| JJ
cholesterol ||| S:720 E:731 ||| NN
,  ||| S:731 E:733 ||| ,
triglycerides  ||| S:733 E:747 ||| NN
and  ||| S:747 E:751 ||| CC
fasting  ||| S:751 E:759 ||| JJ
plasma  ||| S:759 E:766 ||| JJ
glucose  ||| S:766 E:774 ||| NN
in  ||| S:774 E:777 ||| IN
diabetics  ||| S:777 E:787 ||| NNS
and  ||| S:787 E:791 ||| CC
non-diabetics ||| S:791 E:804 ||| JJ
,  ||| S:804 E:806 ||| ,
and  ||| S:806 E:810 ||| CC
glycosylated  ||| S:810 E:823 ||| JJ
haemoglobin  ||| S:823 E:835 ||| NN
in  ||| S:835 E:838 ||| IN
diabetics ||| S:838 E:847 ||| NNS
.  ||| S:847 E:849 ||| .
Improvements  ||| S:849 E:862 ||| NNS
were  ||| S:862 E:867 ||| VBD
maintained  ||| S:867 E:878 ||| VBN
over  ||| S:878 E:883 ||| IN
2  ||| S:883 E:885 ||| CD
years  ||| S:885 E:891 ||| NNS
with  ||| S:891 E:896 ||| IN
rimonabant ||| S:896 E:906 ||| NNS
;  ||| S:906 E:908 ||| :
withdrawal  ||| S:908 E:919 ||| NN
of  ||| S:919 E:922 ||| IN
rimonabant  ||| S:922 E:933 ||| NN
at  ||| S:933 E:936 ||| IN
1  ||| S:936 E:938 ||| CD
year  ||| S:938 E:943 ||| NN
resulted  ||| S:943 E:952 ||| VBD
in  ||| S:952 E:955 ||| IN
a  ||| S:955 E:957 ||| DT
reduction  ||| S:957 E:967 ||| NN
in  ||| S:967 E:970 ||| IN
weight  ||| S:970 E:977 ||| NN
loss  ||| S:977 E:982 ||| NN
until  ||| S:982 E:988 ||| IN
there  ||| S:988 E:994 ||| EX
was  ||| S:994 E:998 ||| VBD
no  ||| S:998 E:1001 ||| DT
difference  ||| S:1001 E:1012 ||| NN
from  ||| S:1012 E:1017 ||| IN
placebo  ||| S:1017 E:1025 ||| NN
at  ||| S:1025 E:1028 ||| IN
2  ||| S:1028 E:1030 ||| CD
years ||| S:1030 E:1035 ||| NNS
.  ||| S:1035 E:1037 ||| .
Psychiatric  ||| S:1037 E:1049 ||| JJ
adverse  ||| S:1049 E:1057 ||| JJ
events  ||| S:1057 E:1064 ||| NNS
were  ||| S:1064 E:1069 ||| VBD
experienced  ||| S:1069 E:1081 ||| VBN
by  ||| S:1081 E:1084 ||| IN
26 ||| S:1084 E:1086 ||| CD
%  ||| S:1086 E:1088 ||| NN
and  ||| S:1088 E:1092 ||| CC
14 ||| S:1092 E:1094 ||| CD
%  ||| S:1094 E:1096 ||| NN
of  ||| S:1096 E:1099 ||| IN
rimonabant  ||| S:1099 E:1110 ||| NN
and  ||| S:1110 E:1114 ||| CC
placebo  ||| S:1114 E:1122 ||| JJ
patients  ||| S:1122 E:1131 ||| NNS
respectively ||| S:1131 E:1143 ||| RB
;  ||| S:1143 E:1145 ||| :
figures  ||| S:1145 E:1153 ||| NNS
for  ||| S:1153 E:1157 ||| IN
symptoms  ||| S:1157 E:1166 ||| NNS
of  ||| S:1166 E:1169 ||| IN
depression  ||| S:1169 E:1180 ||| NN
were  ||| S:1180 E:1185 ||| VBD
9 ||| S:1185 E:1186 ||| CD
%  ||| S:1186 E:1188 ||| NN
and  ||| S:1188 E:1192 ||| CC
5 ||| S:1192 E:1193 ||| CD
%  ||| S:1193 E:1195 ||| NN
respectively ||| S:1195 E:1207 ||| RB
.  ||| S:1207 E:1209 ||| .
Pairwise  ||| S:1209 E:1218 ||| JJ
comparisons  ||| S:1218 E:1230 ||| NNS
of  ||| S:1230 E:1233 ||| IN
orlistat ||| S:1233 E:1241 ||| NN
,  ||| S:1241 E:1243 ||| ,
sibutramine  ||| S:1243 E:1255 ||| NN
and  ||| S:1255 E:1259 ||| CC
rimonabant  ||| S:1259 E:1270 ||| NNS
showed  ||| S:1270 E:1277 ||| VBD
beneficial  ||| S:1277 E:1288 ||| JJ
effects  ||| S:1288 E:1296 ||| NNS
of  ||| S:1296 E:1299 ||| IN
rimonabant  ||| S:1299 E:1310 ||| NN
over  ||| S:1310 E:1315 ||| IN
orlistat  ||| S:1315 E:1324 ||| NN
and  ||| S:1324 E:1328 ||| CC
sibutramine  ||| S:1328 E:1340 ||| NN
for  ||| S:1340 E:1344 ||| IN
weight  ||| S:1344 E:1351 ||| NN
loss  ||| S:1351 E:1356 ||| NN
outcomes ||| S:1356 E:1364 ||| NNS
;  ||| S:1364 E:1366 ||| :
however ||| S:1366 E:1373 ||| RB
,  ||| S:1373 E:1375 ||| ,
response  ||| S:1375 E:1384 ||| NN
hurdles  ||| S:1384 E:1392 ||| NNS
imposed  ||| S:1392 E:1400 ||| VBN
on  ||| S:1400 E:1403 ||| IN
orlistat  ||| S:1403 E:1412 ||| NN
or  ||| S:1412 E:1415 ||| CC
sibutramine  ||| S:1415 E:1427 ||| NN
in  ||| S:1427 E:1430 ||| IN
clinical  ||| S:1430 E:1439 ||| JJ
practice  ||| S:1439 E:1448 ||| NN
may  ||| S:1448 E:1452 ||| MD
not  ||| S:1452 E:1456 ||| RB
have  ||| S:1456 E:1461 ||| VBP
been  ||| S:1461 E:1466 ||| VBN
applied  ||| S:1466 E:1474 ||| VBN
in  ||| S:1474 E:1477 ||| IN
the  ||| S:1477 E:1481 ||| DT
orlistat  ||| S:1481 E:1490 ||| NN
and  ||| S:1490 E:1494 ||| CC
sibutramine  ||| S:1494 E:1506 ||| JJ
trials ||| S:1506 E:1512 ||| NNS
.  ||| S:1512 E:1514 ||| .
The  ||| S:1514 E:1518 ||| DT
manufacturer ||| S:1518 E:1530 ||| NN
's  ||| S:1530 E:1533 ||| POS
Markov  ||| S:1533 E:1540 ||| NNP
cohort  ||| S:1540 E:1547 ||| FW
model  ||| S:1547 E:1553 ||| FW
evaluated  ||| S:1553 E:1563 ||| FW
rimonabant  ||| S:1563 E:1574 ||| FW
versus  ||| S:1574 E:1581 ||| FW
orlistat ||| S:1581 E:1589 ||| FW
,  ||| S:1589 E:1591 ||| ,
sibutramine  ||| S:1591 E:1603 ||| NN
and  ||| S:1603 E:1607 ||| CC
diet  ||| S:1607 E:1612 ||| NN
and  ||| S:1612 E:1616 ||| CC
exercise  ||| S:1616 E:1625 ||| VB
alone  ||| S:1625 E:1631 ||| RB
for  ||| S:1631 E:1635 ||| IN
three  ||| S:1635 E:1641 ||| CD
base-case  ||| S:1641 E:1651 ||| JJ
populations ||| S:1651 E:1662 ||| NNS
.  ||| S:1662 E:1664 ||| .
The  ||| S:1664 E:1668 ||| DT
incremental  ||| S:1668 E:1680 ||| JJ
cost-effectiveness  ||| S:1680 E:1699 ||| JJ
ratio  ||| S:1699 E:1705 ||| NN
( ||| S:1705 E:1706 ||| -LRB-
ICER ||| S:1706 E:1710 ||| NNP
)  ||| S:1710 E:1712 ||| -RRB-
of  ||| S:1712 E:1715 ||| IN
rimonabant  ||| S:1715 E:1726 ||| JJ
varied  ||| S:1726 E:1733 ||| NN
from  ||| S:1733 E:1738 ||| IN
10,534  ||| S:1738 E:1745 ||| CD
pounds  ||| S:1745 E:1752 ||| NNS
to  ||| S:1752 E:1755 ||| TO
13,236  ||| S:1755 E:1762 ||| CD
pounds  ||| S:1762 E:1769 ||| NNS
per  ||| S:1769 E:1773 ||| IN
quality-adjusted  ||| S:1773 E:1790 ||| JJ
life-year  ||| S:1790 E:1800 ||| NN
( ||| S:1800 E:1801 ||| -LRB-
QALY ||| S:1801 E:1805 ||| NNP
)  ||| S:1805 E:1807 ||| -RRB-
versus  ||| S:1807 E:1814 ||| CC
diet  ||| S:1814 E:1819 ||| NN
and  ||| S:1819 E:1823 ||| CC
exercise ||| S:1823 E:1831 ||| NN
,  ||| S:1831 E:1833 ||| ,
to  ||| S:1833 E:1836 ||| TO
8977  ||| S:1836 E:1841 ||| CD
pounds  ||| S:1841 E:1848 ||| NNS
to  ||| S:1848 E:1851 ||| TO
12,138  ||| S:1851 E:1858 ||| FW
pounds  ||| S:1858 E:1865 ||| FW
per  ||| S:1865 E:1869 ||| FW
QALY  ||| S:1869 E:1874 ||| FW
versus  ||| S:1874 E:1881 ||| FW
orlistat ||| S:1881 E:1889 ||| FW
,  ||| S:1889 E:1891 ||| ,
to  ||| S:1891 E:1894 ||| TO
1463  ||| S:1894 E:1899 ||| CD
pounds  ||| S:1899 E:1906 ||| NNS
to  ||| S:1906 E:1909 ||| TO
3908  ||| S:1909 E:1914 ||| CD
pounds  ||| S:1914 E:1921 ||| NNS
per  ||| S:1921 E:1925 ||| IN
QALY  ||| S:1925 E:1930 ||| NNP
versus  ||| S:1930 E:1937 ||| FW
sibutramine ||| S:1937 E:1948 ||| FW
.  ||| S:1948 E:1950 ||| .
In  ||| S:1950 E:1953 ||| IN
subgroup  ||| S:1953 E:1962 ||| JJ
analysis  ||| S:1962 E:1971 ||| NN
there  ||| S:1971 E:1977 ||| EX
was  ||| S:1977 E:1981 ||| VBD
a  ||| S:1981 E:1983 ||| DT
wider  ||| S:1983 E:1989 ||| JJR
variation  ||| S:1989 E:1999 ||| NN
in  ||| S:1999 E:2002 ||| IN
the  ||| S:2002 E:2006 ||| DT
ICER  ||| S:2006 E:2011 ||| NNP
estimates  ||| S:2011 E:2021 ||| NNS
although  ||| S:2021 E:2030 ||| IN
none  ||| S:2030 E:2035 ||| NN
exceeded  ||| S:2035 E:2044 ||| VBD
20,000  ||| S:2044 E:2051 ||| CD
pounds  ||| S:2051 E:2058 ||| NNS
per  ||| S:2058 E:2062 ||| IN
QALY ||| S:2062 E:2066 ||| NNP
.  ||| S:2066 E:2068 ||| .
The  ||| S:2068 E:2072 ||| DT
ICER  ||| S:2072 E:2077 ||| NNP
of  ||| S:2077 E:2080 ||| IN
rimonabant  ||| S:2080 E:2091 ||| NN
remained  ||| S:2091 E:2100 ||| VBD
under  ||| S:2100 E:2106 ||| IN
20,000  ||| S:2106 E:2113 ||| CD
pounds  ||| S:2113 E:2120 ||| NNS
per  ||| S:2120 E:2124 ||| IN
QALY  ||| S:2124 E:2129 ||| NNP
in  ||| S:2129 E:2132 ||| IN
reanalyses  ||| S:2132 E:2143 ||| NN
by  ||| S:2143 E:2146 ||| IN
the  ||| S:2146 E:2150 ||| DT
manufacturer  ||| S:2150 E:2163 ||| NN
and  ||| S:2163 E:2167 ||| CC
the  ||| S:2167 E:2171 ||| DT
ERG ||| S:2171 E:2174 ||| NNP
,  ||| S:2174 E:2176 ||| ,
with  ||| S:2176 E:2181 ||| IN
the  ||| S:2181 E:2185 ||| DT
results  ||| S:2185 E:2193 ||| NNS
sensitive  ||| S:2193 E:2203 ||| JJ
to  ||| S:2203 E:2206 ||| TO
the  ||| S:2206 E:2210 ||| DT
source  ||| S:2210 E:2217 ||| NN
of  ||| S:2217 E:2220 ||| IN
health-related  ||| S:2220 E:2235 ||| JJ
quality  ||| S:2235 E:2243 ||| NN
of  ||| S:2243 E:2246 ||| IN
life  ||| S:2246 E:2251 ||| NN
( ||| S:2251 E:2252 ||| -LRB-
HRQoL ||| S:2252 E:2257 ||| NNP
)  ||| S:2257 E:2259 ||| -RRB-
benefits  ||| S:2259 E:2268 ||| NNS
in  ||| S:2268 E:2271 ||| IN
the  ||| S:2271 E:2275 ||| DT
model ||| S:2275 E:2280 ||| NN
.  ||| S:2280 E:2282 ||| .
Four  ||| S:2282 E:2287 ||| CD
treatment  ||| S:2287 E:2297 ||| NN
strategies  ||| S:2297 E:2308 ||| NNS
were  ||| S:2308 E:2313 ||| VBD
modelled  ||| S:2313 E:2322 ||| VBN
in  ||| S:2322 E:2325 ||| IN
comparisons  ||| S:2325 E:2337 ||| NNS
of  ||| S:2337 E:2340 ||| IN
rimonabant  ||| S:2340 E:2351 ||| FW
versus  ||| S:2351 E:2358 ||| FW
diet  ||| S:2358 E:2363 ||| FW
and  ||| S:2363 E:2367 ||| CC
exercise  ||| S:2367 E:2376 ||| VB
alone  ||| S:2376 E:2382 ||| RB
and  ||| S:2382 E:2386 ||| CC
orlistat  ||| S:2386 E:2395 ||| NNS
and  ||| S:2395 E:2399 ||| CC
sibutramine  ||| S:2399 E:2411 ||| NN
in  ||| S:2411 E:2414 ||| IN
which  ||| S:2414 E:2420 ||| WDT
rimonabant  ||| S:2420 E:2431 ||| NNS
was  ||| S:2431 E:2435 ||| VBD
continued  ||| S:2435 E:2445 ||| VBN
only  ||| S:2445 E:2450 ||| RB
in  ||| S:2450 E:2453 ||| IN
patients  ||| S:2453 E:2462 ||| NNS
achieving  ||| S:2462 E:2472 ||| VBG
5 ||| S:2472 E:2473 ||| CD
%  ||| S:2473 E:2475 ||| NN
weight  ||| S:2475 E:2482 ||| NN
loss  ||| S:2482 E:2487 ||| NN
at  ||| S:2487 E:2490 ||| IN
3 ||| S:2490 E:2491 ||| CD
,  ||| S:2491 E:2493 ||| ,
6 ||| S:2493 E:2494 ||| CD
,  ||| S:2494 E:2496 ||| ,
9  ||| S:2496 E:2498 ||| CD
or  ||| S:2498 E:2501 ||| CC
12  ||| S:2501 E:2504 ||| CD
months ||| S:2504 E:2510 ||| NNS
.  ||| S:2510 E:2512 ||| .
In  ||| S:2512 E:2515 ||| IN
pairwise  ||| S:2515 E:2524 ||| JJ
comparisons  ||| S:2524 E:2536 ||| NNS
rimonabant  ||| S:2536 E:2547 ||| VBP
remained  ||| S:2547 E:2556 ||| VBN
below  ||| S:2556 E:2562 ||| IN
a  ||| S:2562 E:2564 ||| DT
threshold  ||| S:2564 E:2574 ||| NN
of  ||| S:2574 E:2577 ||| IN
30,000  ||| S:2577 E:2584 ||| CD
pounds  ||| S:2584 E:2591 ||| NNS
per  ||| S:2591 E:2595 ||| IN
QALY  ||| S:2595 E:2600 ||| NNP
in  ||| S:2600 E:2603 ||| IN
70 ||| S:2603 E:2605 ||| CD
%  ||| S:2605 E:2607 ||| NN
of  ||| S:2607 E:2610 ||| IN
the  ||| S:2610 E:2614 ||| DT
comparisons  ||| S:2614 E:2626 ||| NNS
reported ||| S:2626 E:2634 ||| VBD
.  ||| S:2634 E:2636 ||| .
The  ||| S:2636 E:2640 ||| DT
results  ||| S:2640 E:2648 ||| NNS
were  ||| S:2648 E:2653 ||| VBD
most  ||| S:2653 E:2658 ||| RBS
sensitive  ||| S:2658 E:2668 ||| JJ
to  ||| S:2668 E:2671 ||| TO
the  ||| S:2671 E:2675 ||| DT
decrement  ||| S:2675 E:2685 ||| NN
applied  ||| S:2685 E:2693 ||| VBD
to  ||| S:2693 E:2696 ||| TO
depression  ||| S:2696 E:2707 ||| NN
and  ||| S:2707 E:2711 ||| CC
the  ||| S:2711 E:2715 ||| DT
costs  ||| S:2715 E:2721 ||| NNS
of  ||| S:2721 E:2724 ||| IN
screening  ||| S:2724 E:2734 ||| NN
for  ||| S:2734 E:2738 ||| IN
depression ||| S:2738 E:2748 ||| NN
.  ||| S:2748 E:2750 ||| .
In  ||| S:2750 E:2753 ||| IN
conclusion ||| S:2753 E:2763 ||| NN
,  ||| S:2763 E:2765 ||| ,
areas  ||| S:2765 E:2771 ||| NNS
of  ||| S:2771 E:2774 ||| IN
uncertainty  ||| S:2774 E:2786 ||| NN
remain  ||| S:2786 E:2793 ||| VBP
in  ||| S:2793 E:2796 ||| IN
relation  ||| S:2796 E:2805 ||| NN
to  ||| S:2805 E:2808 ||| TO
the  ||| S:2808 E:2812 ||| DT
clinical  ||| S:2812 E:2821 ||| JJ
effectiveness  ||| S:2821 E:2835 ||| NN
and  ||| S:2835 E:2839 ||| CC
cost-effectiveness  ||| S:2839 E:2858 ||| JJ
of  ||| S:2858 E:2861 ||| IN
rimonabant ||| S:2861 E:2871 ||| NN
,  ||| S:2871 E:2873 ||| ,
for  ||| S:2873 E:2877 ||| IN
example  ||| S:2877 E:2885 ||| NN
lack  ||| S:2885 E:2890 ||| NN
of  ||| S:2890 E:2893 ||| IN
evidence  ||| S:2893 E:2902 ||| NN
on  ||| S:2902 E:2905 ||| IN
long-term  ||| S:2905 E:2915 ||| JJ
outcomes  ||| S:2915 E:2924 ||| NNS
and  ||| S:2924 E:2928 ||| CC
the  ||| S:2928 E:2932 ||| DT
effect  ||| S:2932 E:2939 ||| NN
of  ||| S:2939 E:2942 ||| IN
rimonabant  ||| S:2942 E:2953 ||| NN
on  ||| S:2953 E:2956 ||| IN
cardiovascular  ||| S:2956 E:2971 ||| JJ
events ||| S:2971 E:2977 ||| NNS
,  ||| S:2977 E:2979 ||| ,
developing  ||| S:2979 E:2990 ||| VBG
diabetes  ||| S:2990 E:2999 ||| NN
and  ||| S:2999 E:3003 ||| CC
mortality ||| S:3003 E:3012 ||| NN
,  ||| S:3012 E:3014 ||| ,
and  ||| S:3014 E:3018 ||| CC
lack  ||| S:3018 E:3023 ||| NN
of  ||| S:3023 E:3026 ||| IN
data  ||| S:3026 E:3031 ||| NNS
on  ||| S:3031 E:3034 ||| IN
the  ||| S:3034 E:3038 ||| DT
HRQoL  ||| S:3038 E:3044 ||| JJ
benefits  ||| S:3044 E:3053 ||| NNS
associated  ||| S:3053 E:3064 ||| VBN
with  ||| S:3064 E:3069 ||| IN
rimonabant ||| S:3069 E:3079 ||| NN
.  ||| S:3079 E:3081 ||| .
The  ||| S:3081 E:3085 ||| DT
lack  ||| S:3085 E:3090 ||| NN
of  ||| S:3090 E:3093 ||| IN
response  ||| S:3093 E:3102 ||| NN
hurdles  ||| S:3102 E:3110 ||| NNS
applied  ||| S:3110 E:3118 ||| VBN
to  ||| S:3118 E:3121 ||| TO
sibutramine  ||| S:3121 E:3133 ||| VB
and  ||| S:3133 E:3137 ||| CC
orlistat  ||| S:3137 E:3146 ||| JJ
means  ||| S:3146 E:3152 ||| NNS
that  ||| S:3152 E:3157 ||| IN
the  ||| S:3157 E:3161 ||| DT
comparator  ||| S:3161 E:3172 ||| JJ
strategies  ||| S:3172 E:3183 ||| NNS
were  ||| S:3183 E:3188 ||| VBD
not  ||| S:3188 E:3192 ||| RB
considered  ||| S:3192 E:3203 ||| VBN
by  ||| S:3203 E:3206 ||| IN
the  ||| S:3206 E:3210 ||| DT
ERG  ||| S:3210 E:3214 ||| NNP
to  ||| S:3214 E:3217 ||| TO
reflect  ||| S:3217 E:3225 ||| VB
their  ||| S:3225 E:3231 ||| PRP$
respective  ||| S:3231 E:3242 ||| JJ
product  ||| S:3242 E:3250 ||| NN
licenses  ||| S:3250 E:3259 ||| NNS
or  ||| S:3259 E:3262 ||| CC
current  ||| S:3262 E:3270 ||| JJ
NHS  ||| S:3270 E:3274 ||| NNP
use ||| S:3274 E:3277 ||| NN
.  ||| S:3277 E:3279 ||| .
The  ||| S:3279 E:3283 ||| DT
NICE  ||| S:3283 E:3288 ||| NNP
guidance  ||| S:3288 E:3297 ||| VBD
issued  ||| S:3297 E:3304 ||| VBN
as  ||| S:3304 E:3307 ||| IN
a  ||| S:3307 E:3309 ||| DT
result  ||| S:3309 E:3316 ||| NN
of  ||| S:3316 E:3319 ||| IN
the  ||| S:3319 E:3323 ||| DT
STA  ||| S:3323 E:3327 ||| NNP
states  ||| S:3327 E:3334 ||| NNS
that  ||| S:3334 E:3339 ||| IN
rimonabant  ||| S:3339 E:3350 ||| NN
is  ||| S:3350 E:3353 ||| VBZ
recommended  ||| S:3353 E:3365 ||| VBN
as  ||| S:3365 E:3368 ||| IN
an  ||| S:3368 E:3371 ||| DT
adjunct  ||| S:3371 E:3379 ||| NN
to  ||| S:3379 E:3382 ||| TO
diet  ||| S:3382 E:3387 ||| NN
and  ||| S:3387 E:3391 ||| CC
exercise  ||| S:3391 E:3400 ||| NN
for  ||| S:3400 E:3404 ||| IN
adults  ||| S:3404 E:3411 ||| NNS
who  ||| S:3411 E:3415 ||| WP
are  ||| S:3415 E:3419 ||| VBP
obese  ||| S:3419 E:3425 ||| VBN
or  ||| S:3425 E:3428 ||| CC
overweight  ||| S:3428 E:3439 ||| NN
and  ||| S:3439 E:3443 ||| CC
who  ||| S:3443 E:3447 ||| WP
have  ||| S:3447 E:3452 ||| VBP
had  ||| S:3452 E:3456 ||| VBN
an  ||| S:3456 E:3459 ||| DT
inadequate  ||| S:3459 E:3470 ||| JJ
response  ||| S:3470 E:3479 ||| NN
to ||| S:3479 E:3481 ||| TO
,  ||| S:3481 E:3483 ||| ,
are  ||| S:3483 E:3487 ||| VBP
intolerant  ||| S:3487 E:3498 ||| VBN
of  ||| S:3498 E:3501 ||| IN
or  ||| S:3501 E:3504 ||| CC
are  ||| S:3504 E:3508 ||| VBP
contraindicated  ||| S:3508 E:3524 ||| VBN
to  ||| S:3524 E:3527 ||| TO
orlistat  ||| S:3527 E:3536 ||| VB
and  ||| S:3536 E:3540 ||| CC
sibutramine ||| S:3540 E:3551 ||| NN
.  ||| S:3551 E:3553 ||| .
